An analytical review on the quantitative techniques for estimation of cilostazol in pharmaceutical preparations and biological samples

• Main Authors: Afreen Afnaan, Nalini C.N.
• Format: Article
• Language: English
• Published: De Gruyter 2021-04-01
• Series: Reviews in Analytical Chemistry
• Subjects: cilostazol; phosphodiesterase iii inhibitors (pde iii); intermittent claudication; pharmaceutical formulations; biological fluids; analytical methods
• Online Access: https://doi.org/10.1515/revac-2021-0128

Cilostazol (CLZ) is a quinolinone derivative possessing anti platelet and vasodilating properties and it is used in the treatment of intermittent claudication. It operates by inhibiting the cyclic guanosine monophosphate (cGMP) dependent phosphodiesterase III which leads to availability of cyclic adenosine monophosphate (cAMP) in blood vessels and platelets owing to vasodilation and reduced calcium-induced contractions. This article illustrates the various reported quantitative methods which can be used to determine cilostazol and its metabolites either alone or in combination forms in pharmaceutical preparation or biological matrices like plasma, serum, and urine. The review covers analytical methods like ultraviolet spectroscopy, fluorescence spectroscopy, electrometric methods, nuclear magnetic resonance spectroscopy, high performance liquid chromatography, high performance thin layer chromatography, ultra-high performance liquid chromatography, and tandem mass spectroscopy from the year 1985 to 2019 with a brief explanation on every analytical method. Among the methods, it was found that most researchers opted for UV and HPLC analytical methods for the estimation of cilostazol.